Sodium cholate-coated Olea europaea polyphenol nanoliposomes: Preparation, stability, release, and bioactivity.

Ultra-flexible nanoliposomes (UNL) coated with sodium cholate were fabricated using the thin film hydration technique to encapsulate oleocanthal (OLEO), oleacein (OLEA), oleuropein (OLEU), and hydroxytyrosol (HT) for improving their stability and bioactivity. Their physicochemical properties were further validated through DLS, FTIR, XRD, TGA, and DSC analyses. Negative-staining TEM imaging revealed well-dispersed UNL with laminar vesicles inside.

Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis.

Background: Recommendations by countries' health technology assessment (HTA) agencies are used to decide which new therapies warrant the allocation of limited health-care resources to make them available through publicly funded health systems. This process is of public health importance for balancing the dual aims of optimising patient outcomes while ensuring financial sustainability. We evaluated which factors affect HTA outcomes and the time to positive HTA outcome, focussing on the role of clinical benefit evaluated with the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Senolytics rejuvenate aging cardiomyopathy in human cardiac organoids.

Background: Human cardiac organoids closely replicate the architecture and function of the human heart, offering a potential accurate platform for studying cellular and molecular features of aging cardiomyopathy. Senolytics have shown potential in addressing age-related pathologies but their potential to reverse aging-related human cardiomyopathy remains largely unexplored.

Methods: We employed human iPSC-derived cardiac organoids (hCOs/hCardioids) to model doxorubicin(DOXO)-induced cardiomyopathy in an aged context.

UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder.

Background: Generalized anxiety disorder (GAD) is a common mental health condition. The endocannabinoid system has become a focus for new therapies, increasing interest in cannabis-based medicinal products (CBMPs). This study uses data from the UK Medical Cannabis Registry (UKMCR) to investigate real-world outcomes and safety of different CBMP formulations in GAD patients.